IL17A and metabolic syndrome: In contrast, several mucosal/antiviral cytokines (e.g., IL-17 and IL-22) depend more directly on CD4+ T cell abundance and are relatively uncoupled from the metabolic status, indicating that dysglycemia and dyslipidemia do not uniformly affect all immune pathways (33, 44).